Results 191 to 200 of about 34,844 (221)

Regulating Tumor Metabolic Reprogramming with Biomimetic Co‐Delivery of Simvastatin and Kynureninase for Immunotherapy

Advanced Science, EarlyView.
After the intravenous injection of biomimetic and pH/ROS‐responsive PTSK@CRM, the nanoparticles can be accumulated in tumors and release Sim and KYNase to inhibit the tumor growth, regulate the metabolism of cholesterol and Kyn, and reverse the immunosuppressive tumor microenvironment.
Jiaxin Yin, Shengcai Yang, Zengguang Liu, Songchen Zhao, Siyu Sun, Ziling Liu, Quanshun Li   +6 more
wiley   +1 more source

Loss of ELF2 drives topotecan resistance in retinoblastoma revealed by genome-wide CRISPR-Cas9 screening. [PDF]

Cell Death Dis
Jiang J, Jiang Z, Luo Q, Chen X, Zhuang J, Chen J, Mu Q, Qiu J, Li Y, Chen S, Zhang P, Yu K, Chen S, Liu GS, Zhuang J.   +14 more
europepmc   +1 more source

Three‐Year Follow‐Up of Neoadjuvant Tislelizumab with Chemotherapy in Locally Advanced Gastric and Gastroesophageal Junction Adenocarcinoma: Revealing Cancer‐Associated Fibroblast Heterogeneity Corresponding to PD‐1 Blockade Efficacy

Advanced Science, EarlyView.
Heterogeneous cancer‐associated fibroblasts orchestrate dual immune microenvironments in LAGC. Abstract The potential for immunotherapy in patients with locally advanced gastric cancer (LAGC) is recently confirmed. To report the 3‐year follow‐up data are aimed from a novel clinical trial. This is a prospective single‐arm phase II trial.
Yao Lin, Xiong Sun, Chengguo Li, Ming Yang, Ke Wu, Ke Liu, Anshu Li, Xiaoming Shuai, Kailin Cai, Zheng Wang, Guobin Wang, Peng Zhang, Jianfeng Shen, Kaixiong Tao, Yuping Yin   +14 more
wiley   +1 more source

Metformin glycyrrhetinic acid binary injectable hydrogel for synergistic tumor immunotherapy via spatiotemporal microenvironment remodeling. [PDF]

Mater Today Bio
Ouyang A, Qin X, Su B, Mo S, Jiang J, Wang Z, Li Y, Lu J, Lin Y, Wang J, Fan L, Jin R.   +11 more
europepmc   +1 more source

Fosinopril mediates antitumor efficacy by inducing GSDME-dependent pyroptosis in NSCLC. [PDF]

Cell Death Discov
Gao Y, Zhai X, Zhang C, Zhao H, Ji B, Sun R, Du X, Du Y, Gao S, Zhang Y, Wang T.   +10 more
europepmc   +1 more source

Unveiling the therapeutic potential of silibinin in head and neck squamous cell carcinoma via network pharmacology. [PDF]

Sci Rep
Zheng Y, Xia Y, Ling J, Zhao H, Zhuo X.
europepmc   +1 more source

Pharmacogenomic Synthetic Lethal Screens Reveal Hidden Vulnerabilities and New Therapeutic Approaches for Treatment of NF1-Associated Tumors. [PDF]

Mol Cancer Ther
Williams KB, Larsson AT, Keller BJ, Chaney KE, Williams RL, Bhunia MM, Draper GM, Jubenville TA, Hudson WA, Georg GI, Moertel CL, Ratner N, Largaespada DA.   +12 more
europepmc   +1 more source

Immune suppression in MTAP-deficient cancers via glutamate metabolism and CXCL10 downregulation. [PDF]

Front Immunol
Chang WH, Zhang J, Hong QS, Chen CH.
europepmc   +1 more source

Guanylate-binding proteins score and a CBFA2T3-included risk model define immune microenvironment and chemosensitivity in lung adenocarcinoma. [PDF]

Eur J Med Res
Shi Z, Shen Y, Liu X, Zhang S.
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Antibody–drug conjugates: Smart chemotherapy delivery across tumor histologies

Ca-A Cancer Journal for Clinicians, 2022
Paolo Tarantino, Roberto Carmagnani Pestana, Shanu Modi   +2 more
exaly